Your browser doesn't support javascript.
loading
Functionally diverse heteromeric traps for ligands of the transforming growth factor-ß superfamily.
Kumar, Ravindra; Grinberg, Asya V; Li, Huiming; Kuo, Tzu-Hsing; Sako, Dianne; Krishnan, Lavanya; Liharska, Katia; Li, Jia; Grenha, Rosa; Maguire, Michelle C; Briscoe, Steven D; Pearsall, R Scott; Herrin, Brantley R; Suragani, Rajasekhar N V S; Castonguay, Roselyne.
Afiliación
  • Kumar R; Acceleron Pharma, Cambridge, MA, USA.
  • Grinberg AV; Acceleron Pharma, Cambridge, MA, USA.
  • Li H; Dragonfly Therapeutics, Waltham, MA, USA.
  • Kuo TH; Acceleron Pharma, Cambridge, MA, USA.
  • Sako D; Acceleron Pharma, Cambridge, MA, USA.
  • Krishnan L; Acceleron Pharma, Cambridge, MA, USA.
  • Liharska K; Acceleron Pharma, Cambridge, MA, USA.
  • Li J; Acceleron Pharma, Cambridge, MA, USA.
  • Grenha R; Dragonfly Therapeutics, Waltham, MA, USA.
  • Maguire MC; Acceleron Pharma, Cambridge, MA, USA.
  • Briscoe SD; Acceleron Pharma, Cambridge, MA, USA.
  • Pearsall RS; Acceleron Pharma, Cambridge, MA, USA.
  • Herrin BR; Acceleron Pharma, Cambridge, MA, USA.
  • Suragani RNVS; Acceleron Pharma, Cambridge, MA, USA.
  • Castonguay R; Cellarity, Cambridge, MA, USA.
Sci Rep ; 11(1): 18341, 2021 09 15.
Article en En | MEDLINE | ID: mdl-34526551
ABSTRACT
Ligands of the transforming growth factor-ß (TGF-ß) superfamily are important targets for therapeutic intervention but present challenges because they signal combinatorially and exhibit overlapping activities in vivo. To obtain agents capable of sequestering multiple TGF-ß superfamily ligands with novel selectivity, we generated soluble, heterodimeric ligand traps by pairing the extracellular domain (ECD) of the native activin receptor type IIB (ActRIIB) alternately with the ECDs of native type I receptors activin receptor-like kinase 4 (ALK4), ALK7, or ALK3. Systematic analysis of these heterodimeric constructs by surface plasmon resonance, and comparison with their homodimeric counterparts, revealed that each type I receptor partner confers a distinct ligand-binding profile to the heterodimeric construct. Additional characterization in cell-based reporter gene assays confirmed that the heterodimeric constructs possessed different profiles of signaling inhibition in vitro, which translated into altered patterns of pharmacological activity when constructs were administered systemically to wild-type mice. Our results detail a versatile platform for the modular recombination of naturally occurring receptor domains, giving rise to inhibitory ligand traps that could aid in defining the physiological roles of TGF-ß ligand sets or be directed therapeutically to human diseases arising from dysregulated TGF-ß superfamily signaling.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Receptores de Activinas / Descubrimiento de Drogas Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ingeniería de Proteínas / Receptores de Activinas / Descubrimiento de Drogas Límite: Animals / Humans Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...